



Medicines & Healthcare products  
Regulatory Agency

MHRA Central Freedom of  
Information Team  
10 South Colonnade  
Canary Wharf  
London  
E14 4PU

[foi.request@mhra.gov.uk](mailto:foi.request@mhra.gov.uk)

[MHRA Website](https://www.mhra.gov.uk)

**Jamie Halliday**  
**request-1449943-e6acce98@whatdotheyknow.com**

Our Ref: **FOI2026/00573**

22 June 2026

Dear **Jamie Halliday**,

Thank you for your Freedom of Information (FOI) request received on 26 May 2026. You wrote:

*Please treat this as a request for information under the Freedom of Information Act 2000.*

*This request concerns cannabis-based products for medicinal use (CBPMs), particularly dried cannabis flower prescribed in private healthcare settings.*

*I am seeking recorded information about whether any national, regulatory, clinical, inspection, safety, licensing or policy guidance exists in relation to maximum THC percentage limits for prescribed CBPM flower.*

*Please provide the following information.*

**1. Recorded guidance on THC percentage limits**

*Please provide any recorded guidance, policy, inspection guidance, regulatory guidance, internal briefing, position statement or other recorded information held by your organisation which refers to:*

*a. maximum THC percentage limits for prescribed CBPM flower; b. THC percentage thresholds such as 20%, 22%, 25%, 26%, 28%, 30% or similar; c. whether prescribers or clinics should restrict patients to a maximum THC percentage; d. whether higher-THC CBPM flower requires additional clinical justification, approval, review, risk assessment or governance oversight.*

**2. Basis for any THC percentage cap or threshold**

*If your organisation holds information suggesting that THC percentage caps or thresholds are used, recommended, expected or considered good practice, please provide recorded information explaining:*

*a. the clinical, regulatory or evidential basis for those caps or thresholds; b. whether such caps are mandatory, advisory, discretionary, or left to prescriber judgement; c. whether any cap differs depending on diagnosis, age, psychiatric history, prior cannabis use, tolerance, treatment response, dose, route of administration, or risk of misuse/diversion.*

### 3. Private clinic prescribing governance

*Please provide recorded information held by your organisation about how private CBPM clinics are expected to justify, review, audit or document decisions involving higher-THC flower.*

*This includes any recorded information about:*

- a. prescribing governance;*
- b. multidisciplinary review;*
- c. specialist sign-off;*
- d. audit requirements;*
- e. risk assessments;*
- f. patient-specific clinical rationale;*
- g. situations where a clinic restricts product strength or THC percentage.*

### 4. No information held

*If your organisation does not hold any recorded information setting, recommending, endorsing or discussing a maximum THC percentage limit for prescribed CBPM flower, please confirm this explicitly.*

*For clarity, I am not requesting patient-identifiable information, individual prescribing records, or information about any specific patient.*

### **MHRA Response**

Information on the supply of unlicensed medicines (including CBPMs) is available from MHRA through the below links.

[Supply unlicensed medicinal products \(specials\) - GOV.UK](#)

[https://assets.publishing.service.gov.uk/media/5e58eefb86650c53a363f77c/Cannabis\\_Guidance\\_unlicensed\\_CBPMs\\_updated\\_2020.pdf](https://assets.publishing.service.gov.uk/media/5e58eefb86650c53a363f77c/Cannabis_Guidance_unlicensed_CBPMs_updated_2020.pdf)

Information to support prescribers of medical cannabis is available from NHS England through the below link.

<https://www.england.nhs.uk/long-read/cannabis-based-products-for-medicinal-use-cbpms/>

Information from the Home Office is also available via the below link:

<https://www.gov.uk/government/publications/cannabis-cbd-and-other-cannabinoids-drug-licensing-factsheet/drug-licensing-factsheet-cannabis-cbd-and-other-cannabinoids>

MHRA holds no information on a maximum THC percentage limits in unlicensed CBPM products.

If you have any queries about this letter, please contact us quoting the reference number above.

Yours sincerely,

MHRA Central Freedom of Information Team  
Medicines & Healthcare products Regulatory Agency

## **Your right to complain under the Freedom of Information Act**

If you are not happy with this response you may request an internal review by e-mailing [foi.request@mhra.gov.uk](mailto:foi.request@mhra.gov.uk) or by writing to: MHRA Central Freedom of Information Team, 10 South, Colonnade, Canary Wharf, London, E14 4PU

Any request for an internal review must be received by us within 40 working days of the date of this letter. Please note we are not obliged to provide a review if it is requested after more than 40 working days.

If you are not content with the outcome of the internal review, you may apply directly to the Information Commissioner's Office for a decision. Generally, the Commissioner cannot make a decision unless you have exhausted our own complaints procedure. The Information Commissioner can be contacted at: The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

Website: [ICO FOI and EIR complaints](#) or telephone 0303 123 1113.

### **Re-use of our information**

The MHRA information supplied in response to your request is subject to Crown copyright. Information created by the MHRA which is disclosed under the Freedom of Information Act is made available for re-use under the Open Government Licence (OGL) v3.0, except where this is otherwise stated. There are some restrictions on re-use under the OGL and these can be viewed here:

<https://www.nationalarchives.gov.uk/doc/open-government-licence/version/3/>